EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo

View source ↗

Summary

EMA recommends withdrawing the marketing authorisation for the cancer medicine Larotrectinib (Lartruvo) due to safety concerns and lack of overall benefit.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Lartruvo (olaratumab)